Board of Directors member

Mike is responsible for an $8 billion global portfolio of medicines that targets the most prevalent health needs facing our society and includes cardio-metabolic and pain therapeutic areas. He oversees over 7,000 colleagues, including Pfizer Country Managers and Country Medical Directors. These colleagues are the “one face of Pfizer” to external stakeholders globally and work together to achieve Pfizer’s purpose: Breakthroughs that change patients’ lives.


Mike’s career has spanned over 25 years in the pharmaceutical industry, with extensive experience in sales, marketing, Healthcare Systems, National Accounts and General Management. He has held several senior positions across both Wyeth and Pfizer. From 2014-2017, Mike was the North America Regional President for Internal Medicine and the US Country Manager. As Chief Marketing Officer for the U.S. Primary Care Business Unit in 2013, Mike oversaw the launch of Eliquis and the return to robust growth for key products, Lyrica and Chantix.

Before taking over the US organisation, Mike held multiple positions in Europe, including serving as the Managing Director for the Nordic countries and the European head of marketing for Specialty Care.

Mike was previously on the board of the National Pharmaceutical Council. He currently serves on the board of the US Healthcare Leadership Council and holds a seat on the Council’s Executive Committee. He is also on the board of the Partnership for America’s Health Care Future and represents Pfizer on the Healthcare Businesswomen’s Association’s Gender Parity Collaborative.


We are ViiV Healthcare: 100% dedicated to HIV medicines and research and focused on people living with HIV and AIDS.

Together we are engaged in the HIV response throughout the world, supported by a team of over 1,100 dedicated ViiV Healthcare staff working across the globe.

Discover more about who we are, the work we do and what we're doing to advance HIV science, support the delivery of HIV treatment and care; and work with partners to address the stigma and discrimination faced by people living with HIV.